Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia
Open-label, no control groupHumansTopical
- Design
- Open-label, no control group
- Subjects
- 8 patients with facial postherpetic neuralgia
- Dose used in the study
- A cream containing the cannabinoid receptor agonist N-palmitoylethanolamine, applied as adjuvant therapy
- Duration
- Not stated in the abstract
- What was measured
- Burning pain, on a visual analogue scale.
What the authors reported
This open-label trial found:
- 5 of 8 patients (62.5%) responded to treatment.
- Among responders, pain fell by an average of 87.8%.
- The cream was tolerated by all patients, with no unpleasant sensations or adverse events reported.
Limits of this study
Very small, open-label trial with no control cream, used alongside patients' existing analgesic therapy rather than tested alone. Duration and dosing frequency are not given in the abstract. Facial postherpetic neuralgia mixes burning pain and itch, and this entry is filed under both.
Source
PubMed 19744255 · doi:10.1111/j.1610-0387.2009.07213.x
Entry checked against the English abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.